Phase II trial of cisplatin and etoposide in patients with metastatic melanoma Journal Article
| Authors: | Eton, O.; Bajorin, D. F.; Chapman, P. B.; Cody, B. V.; Houghton, A. N. |
| Article Title: | Phase II trial of cisplatin and etoposide in patients with metastatic melanoma |
| Abstract: | Fourteen patients with metastatic melanoma were treated with cisplatin and etoposide by bolus intravenous infusion daily for 5 consecutive days each month. All patients were evaluable for toxicity and twelve for response. Eight patients were treated with cisplatin 20 mg/m2 and etoposide 100 mg/m2 daily. Because of excessive myelosuppression, the daily dose of etoposide was reduced to 75 mg/m2 in the remaining six patients. There were no major responses among 12 evaluable patients (major response rate ≤ 24% with 95% confidence). The median time to progression was one month. One patient with a liver metastasis had a minor response lasting 6 + months. The combination of cisplatin and etoposide in these doses and schedule lacked sufficient clinical efficacy in the treatment of metastatic melanoma. © 1991 Kluwer Academic Publishers. |
| Keywords: | adult; clinical article; aged; cisplatin; chemotherapy; melanoma; metastasis; phase 2 clinical trial; bone marrow suppression; etoposide; antineoplastic combined chemotherapy protocols; phase ii; intravenous drug administration; middle age; drug evaluation; human; male; female; priority journal; article; support, u.s. gov't, p.h.s. |
| Journal Title: | Investigational New Drugs |
| Volume: | 9 |
| Issue: | 1 |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Date Published: | 1991-02-01 |
| Start Page: | 101 |
| End Page: | 103 |
| Language: | English |
| DOI: | 10.1007/bf00194558 |
| PUBMED: | 2026478 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 27 September 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work